SCHEMBL3422912

SCHEMBL3422912

NCCCCCC(CO)CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
DNM1 Q05193 4/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
TSHR P16473 2/20 0.44
BLM P54132 1/20 0.44
GSR P00390 1/20 0.41
CPB2 Q96IY4 2/20 0.40
RNPEP Q9H4A4 1/20 0.39
NFKB1 P19838 1/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15861710 1.00 LMNA (0.50) LMNADNM1CA12CA1CA2
SCHEMBL5015299 1.00 LMNA (0.50) LMNADNM1CA12CA1CA2
SCHEMBL183936 0.97 LMNA (0.46) LMNADNM1CA12CA1CA2
SCHEMBL1050623 0.88
SCHEMBL27885636 0.86 LMNA (0.42) LMNADNM1CA12CA1CA2
SCHEMBL20639323 0.86 LMNA (0.48) LMNADNM1CA12CA1CA2
SCHEMBL17062955 0.85 ALDH1A1 (0.60) LMNADNM1TSHRBLMCPB2
SCHEMBL17062963 0.84 LMNA (0.64) LMNADNM1TSHRBLMCPB2
SCHEMBL31526867 0.82 LMNA (0.48) LMNADNM1CA12CA1CA2
SCHEMBL8061903 0.82 ALDH1A1 (0.62) LMNADNM1TSHRGSRCPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687609-B1 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND EPOCH BIOSCIENCES INC (US) 2014-12-10 EP disclosed
US-7759126-B2 Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for amplification (or PCR) analysis ELITECH HOLDING B.V. (NL) 2010-07-20 US disclosed
US-20080293586-A1 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND EPOCH BIOSCIENCES, INC. (US) 2008-11-27 US disclosed
US-7381818-B2 Fluorescent probes containing 5′-minor groove binder, fluorophore and quenching moieties and methods of use thereof EPOCH BIOSCIENCES, INC. (US) 2008-06-03 US disclosed
EP-1687609-A2 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND Epoch Biosciences, Inc. (US) 2006-08-09 EP disclosed
US-20050214797-A1 Fluorescent probes for DNA detection by hybridization with improved sensitivity and low background EPOCH BIOSCIENCES, INC (US) 2005-09-29 US disclosed
WO-2005043127-A2 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND EPOCH BIOSCIENCES, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293586-A1 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND SSBP1, DDB1, DNA2 LMNA 318/4885DNM1 1579/4885CA12 2142/4885
US-20050214797-A1 Fluorescent probes for DNA detection by hybridization with improved sensitivity and low background SSBP1, DDB1, DNA2 LMNA 318/4885DNM1 1579/4885CA12 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.